Small molecule · developed by CorMedix Therapeutics
CRMD-001 is a formulation of deferiprone, given as immediate-release and extended-release tablets. It is studied in contrast-induced acute kidney injury in subjects undergoing angiography.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT01146925 | Phase 2 | Contrast-Induced Acute Kidney Injury | Completed | CRMD |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Contrast-Induced Acute Kidney Injury
Updated Nov 8, 2026. Something wrong or missing? Report it on the CRMD page.
See CRMD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
CRMD catalysts and pipeline →